ATE526320T1 - Antagonisten des vanilloidrezeptors vom subtyp 1 (vr1), und anwendungen davon - Google Patents

Antagonisten des vanilloidrezeptors vom subtyp 1 (vr1), und anwendungen davon

Info

Publication number
ATE526320T1
ATE526320T1 AT06759574T AT06759574T ATE526320T1 AT E526320 T1 ATE526320 T1 AT E526320T1 AT 06759574 T AT06759574 T AT 06759574T AT 06759574 T AT06759574 T AT 06759574T AT E526320 T1 ATE526320 T1 AT E526320T1
Authority
AT
Austria
Prior art keywords
subtype
antagonists
applications
vanilloid receptor
vanilloid
Prior art date
Application number
AT06759574T
Other languages
English (en)
Inventor
Arthur Gomtsyan
Richard Perner
John Koenig
Margaret Chi-Ping Hsu
Dilini Fernando
Chih-Hung Lee
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of ATE526320T1 publication Critical patent/ATE526320T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT06759574T 2005-05-11 2006-05-10 Antagonisten des vanilloidrezeptors vom subtyp 1 (vr1), und anwendungen davon ATE526320T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67970805P 2005-05-11 2005-05-11
PCT/US2006/018256 WO2006122250A2 (en) 2005-05-11 2006-05-10 Antagonists of the vanilloid receptor subtype 1 (vr1) and uses thereof

Publications (1)

Publication Number Publication Date
ATE526320T1 true ATE526320T1 (de) 2011-10-15

Family

ID=37056909

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06759574T ATE526320T1 (de) 2005-05-11 2006-05-10 Antagonisten des vanilloidrezeptors vom subtyp 1 (vr1), und anwendungen davon

Country Status (14)

Country Link
US (3) US7504520B2 (de)
EP (1) EP1885704B1 (de)
JP (1) JP4862042B2 (de)
KR (1) KR20080014024A (de)
CN (2) CN102516192A (de)
AT (1) ATE526320T1 (de)
AU (1) AU2006243987B2 (de)
BR (1) BRPI0608810A2 (de)
CA (1) CA2608091A1 (de)
IL (1) IL187208A0 (de)
MX (1) MX2007014048A (de)
NZ (1) NZ563200A (de)
WO (1) WO2006122250A2 (de)
ZA (1) ZA201102735B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060229305A1 (en) * 2005-03-22 2006-10-12 Markus Berger Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
KR20080019213A (ko) 2005-05-09 2008-03-03 아칠리온 파르마세우티칼스 인코포레이티드 티아졸 화합물 및 그 사용방법
EP2012778A4 (de) * 2006-04-18 2011-08-10 Abbott Lab Antagonisten des vanilloid-rezeptor-subtyps-1 (vr1) und ihre verwendung
MX2009012613A (es) 2007-05-22 2010-04-21 Achillion Pharmaceuticals Inc Tiazoles substituidos por heteroarilo y su uso como agentes antivirales.
US7998993B2 (en) 2007-10-25 2011-08-16 Abbott Laboratories TRPV1 antagonists
JP5643112B2 (ja) 2008-01-28 2014-12-17 アモーレパシフィック コーポレイションＡｍｏｒｅｐａｃｉｆｉｃ Ｃｏｒｐｏｒａｔｉｏｎ バニロイド受容体としての新規化合物、その異性体または薬剤学的に許容し得る塩、及びこれを含有する医薬組成物
US8106209B2 (en) 2008-06-06 2012-01-31 Achillion Pharmaceuticals, Inc. Substituted aminothiazole prodrugs of compounds with anti-HCV activity
JP5438103B2 (ja) 2008-07-02 2014-03-12 アモーレパシフィック コーポレイション バニロイド受容体アンタゴニストとしての新規化合物、その異性体またはその薬学的に許容される塩、並びにそれを含む医薬組成物
WO2010021864A1 (en) * 2008-08-20 2010-02-25 Merck Sharp & Dohme Corp. Non-amidic linkers with branched termini as cgrp receptor antagonists
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
CN102762572A (zh) 2010-02-01 2012-10-31 诺瓦提斯公司 作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
JP5748777B2 (ja) 2010-02-02 2015-07-15 ノバルティス アーゲー Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
UY33966A (es) 2011-03-25 2012-10-31 Abbott Lab Antagonistas del receptor transitorio potencial de vanilloides 1 (trpv1)
EP2714667B1 (de) 2011-05-27 2020-11-25 Laxman S. DESAI Aminooxazolhemmer von cyclinabhängigen kinasen
US8969325B2 (en) 2011-12-19 2015-03-03 Abbvie Inc. TRPV1 antagonists
US8859584B2 (en) 2011-12-19 2014-10-14 Abbvie, Inc. TRPV1 antagonists
US8796328B2 (en) 2012-06-20 2014-08-05 Abbvie Inc. TRPV1 antagonists
WO2015074064A2 (en) 2013-11-18 2015-05-21 Bair Kenneth W Tetrahydroquinoline compositions as bet bromodomain inhibitors
US9422281B2 (en) 2013-11-18 2016-08-23 Forma Therapeutics, Inc. Benzopiperazine compositions as BET bromodomain inhibitors
AU2017363145B2 (en) 2016-11-16 2024-02-15 Allele Biotechnology & Pharmaceuticals, Inc. Induction of pancreatic beta cells by stem cell differentiation with RNA
IL266477B2 (en) * 2016-11-16 2026-01-01 Allele Biotechnology & Pharmaceuticals Inc Induction of hepatocytes through stem cell differentiation with RNA
GB201704476D0 (en) 2017-03-21 2017-05-03 Antabio Sas Chemical compounds
IL281770B2 (en) 2018-09-25 2025-03-01 Antabio Sas Indane derivatives for use in the treatment of bacterial infection

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5151440A (en) * 1990-02-28 1992-09-29 Allergan, Inc. Method for reducing or maintaining intraocular pressure in the mammalian eye by administering pharmaceutical compositions containing 2-(2-alkylphenylamino)-oxazolines, 2-(2-alkylphenyl-amino)-thiazolines and 2-(2-alkylphenylamino)-imidazolines
FR2754258B1 (fr) * 1996-10-08 1998-12-31 Sanofi Sa Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
AU2002213467A1 (en) * 2000-10-11 2002-04-22 Chemocentryx, Inc. Modulation of ccr4 function
US7144903B2 (en) * 2001-05-23 2006-12-05 Amgen Inc. CCR4 antagonists
US6881746B2 (en) * 2001-12-03 2005-04-19 Novo Nordick A/S Glucagon antagonists/inverse agonists
CA2515215A1 (en) * 2003-02-10 2004-08-26 Amgen Inc. Vanilloid receptor ligands and their use in treatments
EP1628666B1 (de) * 2003-05-14 2015-09-23 NeuroGenetic Pharmaceuticals, Inc. Verbindungen und ihre verwendungen zur modulierung von amyloid beta
US20050228031A1 (en) * 2004-04-13 2005-10-13 Bilodeau Mark T Tyrosine kinase inhibitors
US7439360B2 (en) * 2004-10-15 2008-10-21 Amgen Inc. Vanilloid receptor ligands and their use in treatments

Also Published As

Publication number Publication date
US20060281799A1 (en) 2006-12-14
CN101248052A (zh) 2008-08-20
JP2008540562A (ja) 2008-11-20
NZ563200A (en) 2011-04-29
BRPI0608810A2 (pt) 2010-01-26
HK1114837A1 (en) 2008-11-14
ZA201102735B (en) 2012-12-27
CN102516192A (zh) 2012-06-27
WO2006122250A2 (en) 2006-11-16
US7504520B2 (en) 2009-03-17
KR20080014024A (ko) 2008-02-13
AU2006243987A8 (en) 2006-11-16
AU2006243987A1 (en) 2006-11-16
AU2006243987B2 (en) 2011-11-24
JP4862042B2 (ja) 2012-01-25
WO2006122250A3 (en) 2007-03-29
IL187208A0 (en) 2008-02-09
EP1885704A2 (de) 2008-02-13
CA2608091A1 (en) 2006-11-16
EP1885704B1 (de) 2011-09-28
US7902236B2 (en) 2011-03-08
US20100010055A1 (en) 2010-01-14
MX2007014048A (es) 2008-02-05
US20110144057A1 (en) 2011-06-16

Similar Documents

Publication Publication Date Title
ATE526320T1 (de) Antagonisten des vanilloidrezeptors vom subtyp 1 (vr1), und anwendungen davon
ATE451381T1 (de) Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
NO20072435L (no) CGRP-reseptorantagonister
ATE466860T1 (de) Cgrp-rezeptorantagonisten
ATE537170T1 (de) Cgrp-rezeptorantagonisten
CY1110398T1 (el) Ενωσεις για την αγωγη της δυσλιπιδαιμιας
NO20071476L (no) Antidiuretiske midler.
ATE463495T1 (de) Oxadiazolylpyrazolopyrimidine als mglur2- antagonisten
DE602005020655D1 (de) Carboxamid-spirolactam-cgrp-rezeptor-antagonisten
MX2007011023A (es) 2-(4-oxo-4h-quinazolin-3-il) acetamidas y su uso como antagonistas de vasopresin v3.
EA200901124A1 (ru) Соединения формулы (i) в качестве ингибиторов серинпротеазы
ATE376833T1 (de) Chinazolinon-derivate als vanilloid-antagonisten
ATE503755T1 (de) Cgrp-rezeptorantagonisten
HRP20080529T3 (en) Amide prodrug of gemcitabine, compositions and use thereof
EP1802372A4 (de) Cgrp-rezeptorantagonisten
DE602005010421D1 (de) Neue Cysteine Protease Hemmers und ihre therapeutische Anwendungen
EA200801365A1 (ru) Замещенные 5-фенил-3,6-дигидро-2-оксо-6h-1,3,4-тиадиазины
ATE466853T1 (de) Cgrp-rezeptorantagonisten
ITMI20041231A1 (it) Antagonisti del recettore dei vanilloidi trpv1
ATE398646T1 (de) Nicht entflammbare zusammensetzung und verwendung davon
SE0303488D0 (sv) New use 1X

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties